XEC: A New Era in the COVID-19 Pandemic

Dec 21, 2024
XEC: The Next Chapter in the COVID-19 Story – Are We Ready?
The XEC COVID-19 variant is a new subvariant of the Omicron strain, first identified in Germany in June 2024. It has since spread rapidly across Europe and the United States

Here are some key points about the XEC variant:
  1. Recombinant Nature: XEC is a recombinant strain, meaning it is a hybrid of two pre-existing subvariants, KP.3.3 and KS.1.1. This recombination can lead to significant genetic changes, potentially giving the new variant an advantage over others.
  2. Transmission and Prevalence: XEC is highly transmissible and has been increasing in prevalence. By late November 2024, it accounted for approximately 38% of COVID-19 infections in the U.S., making it the second most prevalent strain after KP.3.1.1
  3. Symptoms and Severity: So far, there is no evidence that XEC causes different symptoms or more severe disease compared to other recent strains. However, COVID-19 remains a concern, especially for older adults and those with compromised immune systems
  4. Vaccination: Health experts recommend getting the updated COVID-19 vaccines, which were made available in August 2024, to protect against the virus, including the XEC variant
 
Here are some recent papers discussing the XEC COVID-19 variant, published in high-impact journals:
  1. "What to Know About XEC, the New SARS-CoV-2 Variant Expected to Dominate Winter’s COVID-19 Wave" - Published in JAMA Network on November 22, 2024, this paper provides an overview of the XEC variant, its origins, and its potential impact on the upcoming winter season.
  2. "Executive Summary Initial Risk Evaluation of XEC" - This report by the World Health Organization, published on December 9, 2024, evaluates the public health risk posed by the XEC variant and its prevalence globally